Gsa Capital Partners LLP Zentalis Pharmaceuticals, Inc. Transaction History
Gsa Capital Partners LLP
- $1.43 Billion
- Q2 2025
A detailed history of Gsa Capital Partners LLP transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 1,133,375 shares of ZNTL stock, worth $1.76 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
1,133,375
Previous 541,975
109.12%
Holding current value
$1.76 Million
Previous $862,000
52.55%
% of portfolio
0.09%
Previous 0.08%
Shares
10 transactions
Others Institutions Holding ZNTL
# of Institutions
123Shares Held
60.6MCall Options Held
0Put Options Held
22K-
Matrix Capital Management Company, LP Waltham, MA14MShares$21.6 Million8.42% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$7.47 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.48MShares$5.39 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.88MShares$4.47 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA2.8MShares$4.34 Million0.01% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $88.3M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...